XML 17 R6.htm IDEA: XBRL DOCUMENT v3.19.2
UNAUDITED CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
9 Months Ended
Apr. 30, 2019
Apr. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES    
Net (Loss) Income $ (5,755,312) $ 21,129,021
Adjustments to reconcile net (loss) income to net cash used in operating activities:    
Depreciation and amortization 550,285 17,514
Impairment of long-lived assets 99,519
Impairment of goodwill
Stock compensation expense 1,530,312
Changes in fair value of contingent purchase consideration (15,147,591) (23,350,122)
Amortization of debt discount 1,128,613
Non-cash interest expense from issuance on debt (derivative) 959,974
Change in fair value of derivative liabilities - convertible notes (1,034,180)
Change in fair value of derivative liabilities - convertible warrants (95,986)
Change in fair value of derivative liabilities - downside protection 570,112
Changes in operating assets and liabilities, net of effect of acquisitions:    
Accounts receivable 735,317
Inventory 1,239,411 (2,011)
Accounts payable and accrued expenses 7,108,042 673,282
Accrued interest on notes receivable (38,401)
Other current assets 106,160 (139,848)
Other assets, net (21,597)
Other current liabilities 4,702
Other noncurrent liabilities 2,233
Net cash used in operating activities (8,058,387) (1,672,164)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of property and equipment (285,670) (8,553)
Purchase of intangible assets (26,487)
Disposal of property and equipment 252,012
Disposal of intangible assets 62,091
Cash received in acquisition of a business, net of cash paid 2,280,425
Net cash provided by (used in) investing activities 2,282,371 (8,553)
CASH FLOWS FROM FINANCING ACTIVITIES    
Loan proceeds from related party (3,305) 145,803
Payment of notes payable (27,248)
Proceeds from note payable 5,929,910
Investment in subsidiary by noncontrolling interest 228,789 213,403
Net cash provided by financing activities 6,128,146 359,206
Effects of currency translation on cash and cash equivalents 9,342 9,779
Net increase (decrease) in cash and cash equivalents 361,472 (1,311,732)
Cash and cash equivalents, beginning of period 1,046,365 2,879,165
Cash and cash equivalents, end of period 1,407,837 1,567,433
Supplemental Disclosure of Cash Flow Information    
Antigen dividend 320,000
Conversion of HDS debt and issuance of call option 14,056,113
Acquisition of Veneto through issuance of debt
Acquisition of Regentys through issuance of debt
Acquisition of Olaregen through issuance of debt